"Each attack can result in potentially irreversible consequences -- causing blindness or losing the ability to walk -- so preventing relapse is the primary goal," said Michael Levy at Massachusetts General Hospital. "There is now for the first time an FDA-approved treatment available to NMOSD patients to help reduce the risk of relapse."
Price: 126.06, Change: +0.72, Percent Change: +0.57
|--Analyst Actions: Goldman Sachs Lowers HP Price Tar...|
|Sector Update: Energy|
|Qualcomm Gets FTC Antitrust Ruling Enforcement Postp...|
|Street Color: Oil Losing Ground as Trade War Heats Up|
|Insider Trends: Insider at Advance Auto Parts Dispos...|